[1] Kansara, M., Teng, M. W., Smyth, M. J. & Thomas, D. M. Translational biology of osteosarcoma. Nat Rev Cancer 14, 722–735 (2014).[2] Gaspar, N. et al. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.European Journal of Cancer 88, 57–66 (2018).[3] Meyers, P. A. et al. Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate. JCO 23, 2004–2011 (2005).[4] Bacci, G. & Lari, S. Current Treatment of High Grade Osteosarcoma of the Extremity: Review. Journal of Chemotherapy 13, 235–243 (2001).[5] Bishop, M. W., Janeway, K. A. & Gorlick, R. Future directions in the treatment of osteosarcoma. Current Opinion in Pediatrics 28, 26 (2016).[6] Luetke, A., Meyers, P. A., Lewis, I. & Juergens, H. Osteosarcoma treatment – Where do we stand? A state of the art review. Cancer Treatment Reviews 40, 523–532 (2014).[7] Paget, S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8, 98–101 (1989).[8] Alfranca, A. et al. Bone microenvironment signals in osteosarcoma development. Cell Mol Life Sci 72, 3097–3113 (2015).[9] Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication | Nature Cell Biology. https://www.nature.com/articles/s41556-018-0250-9.[10] Corre, I., Verrecchia, F., Crenn, V., Redini, F. & Trichet, V. The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem. Cells 9, 976 (2020).